Autoimmune CAR T companies compete for resources

The 30-plus companies running CAR T cell trials in autoimmune diseases signal growing conviction in the modality’s paradigm-shifting potential. However, the rush has also sparked concerns about wasted resources, recruitment challenges and market opportunity.

According to the CEOs of two companies with leading autologous CD19 CAR T therapies for autoimmune diseases, the crowded field comes as no surprise. But with competition intensifying, an accelerated development strategy is now critical — not just for commercial success, but for overcoming clinical hurdles as well...